Mutations in tumor protein 53 (TP53) and Titin (TTN) genes play pivotal roles in LUAD, influencing tumor aggressiveness and prognosis, and the patient’s response to treatments, including chemotherapy and immunotherapy[10,11]. Here, TP53 is linked to neoplasm.